Table 2.
Demographic, clinical, and environmental factors among study subjects.a
| 2006 Enrollment Cohort |
2007 Enrollment Cohort |
Total | |
|---|---|---|---|
| N=260 | N=655 | N=915 | |
| Gender (n, % male) | 136 (52) | 326 (50) | 462 (50) |
| Assigned to study drug (motavizumab) |
176 (68) | 435 (66) | 611 (67) |
| Age on January 1, 2009 (in months; median, range) |
26.3 (24.1–31.2) | 15.4 (12.2–20.6) | 16.9 (12.2–31.2) |
| Breastfed as an infant (n, %) | 224 (86) | 561 (86) | 785 (86) |
| Hospitalized prior to enrollment in parent trial (n, %) |
30 (13) | 62 (11) | 92 (12) |
| Attending daycare(n, %) | 5 (2) | 19 (3) | 24 (3) |
| Siblings <6 years old at home(n, %) | 168 (65) | 436 (67) | 604 (66) |
| Smoker in the household | 53 (20) | 123 (19) | 176 (19) |
| Mother smoked during pregnancy | 11 (4) | 27 (4)b | 38 (4) |
| Wood/coal stove in home | 155 (60) | 409 (62) | 564 (62) |
| Family member with asthma* | 92 (35) | 180 (27) | 272 (30) |
| Family member with wheeze | 61 (23) | 114 (17)b | 175 (19) |
| Family member with hay fever* | 36 (14) | 60 (9)b | 196 (10) |
| Family member with eczema | 31 (12) | 73 (11) | 104 (11) |
| Assigned to motavizumab treatment | 176 (68) | 435 (66) | 611 (67) |
a
Baseline demographic and exposure data were collected by parent or guardian interview at the time of enrollment.
b
Data not available for 1 subject.
*
p<0.05 comparing 2006 cohort 2007 cohort; p≥0.05 for all other variables.